An estimated 18,000 people in the United States annually suffer from new injuries to their spinal cords. Unfortunately for ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has ...

Zai Lab Limited (NASDAQ:ZLAB) said on Monday that China’s National Medical Products Administration has accepted the label ...

KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with ...

Nuvalent Inc. has identified proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer.

"When the first BTK inhibitor got approved by the FDA for other conditions, we all saw that follicular lymphoma should be the ...

HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has completed enrollment of the registration phase of its Phase II trial of savolitinib in gastric cancer ...

ArriVent BioPharma, Inc.’s AVBP share price has surged by 6.01%, which has investors questioning if this is right time to ...